Veraxa Biotech AG VRXA
0.99 USD +0.04 (+4.21%)
Nov 5, 2026, 11:10 AM EST
0.98 Day range 1.03
0.95 52-week range 27.36
- YTD
- -90.72%
- 1 year
- -90.59%
- Market cap
- 139.99M
- EPS (ttm)
- -0.57
- YTD return
- -90.72%
- 1-year return
- -90.59%
- Volume
- 60.05K
- Avg volume
- 257.11K
- Open
- 1.01
- Previous close
- 0.95
- Day's range
- 0.98 – 1.03
- 52-week range
- 0.95 – 27.36
2Y -9.0498 (-90.14%)
Financials — quick view
VRXA Revenue — quarterly 23.43K
VRXA Net income — quarterly -75.72M
VRXA EPS — quarterly -4.89
News
12 Health Care Stocks Moving In Friday's Intraday Session 
VERAXA Biotech Announces Initial Results From Strategic Research Collaboration To Develop Next-Generation Antibody Oligonucleotide Conjugates For Autoimmune And Chronic Immune Diseases; In Early In Vitro Studies, An AOC Candidate Demonstrated Greater Potency 
VERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy Discovery 
VERAXA Gets German Regulatory Feedback On Cancer Therapy Plan 
VERAXA Biotech Partners With AI-Driven Computational R&D Partner Ardigen To Support Its Growing BiTAC Pipeline Of T Cell Engagers And Antibody Drug Conjugates 
FB Financial, Smith Micro Software And 3 Stocks To Watch Heading Into Monday - VERAXA Biotech Appoints Carl Von Halem As Interim CFO, Succeeding Torsten Bürgermeister
Penguin Solutions, Beazer Homes, Alibaba And Other Big Stocks Moving Higher On Wednesday 
12 Health Care Stocks Moving In Tuesday's Intraday Session - VERAXA Biotech Channels Investment Into BiTAC Portfolio, Eyes BiTAC-TCE Candidate VXA-102 IND/CTA-Ready By 2028
Your note
Sign in to keep a note on VRXA — it syncs with the Stock Master app.